# Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

> **NCT06363123** · — · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 2700 (estimated)

## Conditions studied

- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Thyroid Cancer
- Gastric Cancer
- Cervical Cancer
- Liver Cancer
- Pancreatic Cancer
- Cholangiocarcinoma
- Prostate Cancer
- Esophageal Cancer
- Ovarian Cancer
- Renal Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06363123
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-29
- **Primary completion:** 2024-10
- **Final completion:** 2025-04
- **Target enrollment:** 2700 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363123, "Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06363123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*